{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:50:32Z","timestamp":1792104632642,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12655"],"award-info":[{"award-number":["24K12655"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06939"],"award-info":[{"award-number":["22K06939"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10293"],"award-info":[{"award-number":["24K10293"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06432"],"award-info":[{"award-number":["23K06432"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26K02551"],"award-info":[{"award-number":["26K02551"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06969"],"award-info":[{"award-number":["22K06969"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K12794"],"award-info":[{"award-number":["25K12794"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12689"],"award-info":[{"award-number":["24K12689"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101074","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:51:38Z","timestamp":1787925098000},"page":"101074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-1255","authenticated-orcid":false,"given":"Yoshitaka","family":"Utsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakaguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Sukeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ushigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-9738","authenticated-orcid":false,"given":"Toshitaka","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncy.22288","article-title":"Salivary duct carcinoma: updates in histology, cytology, molecular biology, and treatment","volume":"128","author":"Nakaguro","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.modpat.2026.101074_bib2","series-title":"WHO Classification of Tumours Editorial Board","first-page":"225","author":"Chiosea","year":"2024"},{"issue":"9","key":"10.1016\/j.modpat.2026.101074_bib3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","article-title":"HER2-targeted therapies beyond breast cancer: an update","volume":"21","author":"Yoon","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"35","key":"10.1016\/j.modpat.2026.101074_bib4","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib5","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.18632\/oncotarget.22927","article-title":"Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas","volume":"9","author":"Shimura","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.modpat.2026.101074_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41379-021-00999-0","article-title":"ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100273","article-title":"ERBB2 amplification and HER2 expression in salivary duct carcinoma: evaluation of scoring guidelines and potential for expanded anti-HER2 therapy","volume":"36","author":"McAfee","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2026.101074_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2025.107280","article-title":"The impact of HER2-low expression in salivary duct carcinoma: clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy","volume":"165","author":"Kano","year":"2025","journal-title":"Oral Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II Trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jjco\/hyaf106","article-title":"Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer","volume":"55","author":"Kano","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"19","key":"10.1016\/j.modpat.2026.101074_bib12","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/cncr.34892","article-title":"A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas","volume":"129","author":"Lee","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.modpat.2026.101074_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106612","article-title":"HER2-targeted therapies for salivary gland cancers","volume":"148","author":"Filippini","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.modpat.2026.101074_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102993","article-title":"Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review","volume":"139","author":"Kanno","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"10.1016\/j.modpat.2026.101074_bib16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment, and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"issue":"22","key":"10.1016\/j.modpat.2026.101074_bib18","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib19","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1309\/AJCP51HCGPOPWSCY","article-title":"Clinicopathologic Significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","article-title":"HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma","volume":"166","author":"Hou","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib24","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00428-021-03036-2","article-title":"Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer","volume":"479","author":"Horii","year":"2021","journal-title":"Virchows Arch"},{"issue":"7","key":"10.1016\/j.modpat.2026.101074_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100785","article-title":"Not all HER2-positive breast cancers are the same: intratumoral heterogeneity, low-level HER2 amplification, and their impact on neoadjuvant therapy response","volume":"38","author":"Dai","year":"2025","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101074_bib27","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10120-018-0887-x","article-title":"Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2-positive gastric cancer","volume":"22","author":"Yagi","year":"2019","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib29","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10120-022-01298-6","article-title":"Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab","volume":"25","author":"Bang","year":"2022","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-017-2151-x","article-title":"Prognostic impact of HER-2 subclonal amplification in breast cancer","volume":"471","author":"Di Oto","year":"2017","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.modpat.2026.101074_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100299","article-title":"HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer","volume":"36","author":"Shen","year":"2023","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101074_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/pin.12195","article-title":"Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma","volume":"64","author":"Kondo","year":"2014","journal-title":"Pathol Int"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/1078-0432.CCR-25-1982","article-title":"Advances in targeting HER2 across cancer subtypes: a pan-tumor approach","volume":"32","author":"Adesoye","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00428-021-03104-7","article-title":"Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?","volume":"479","author":"Antol\u00edn","year":"2021","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41379-020-00728-z","article-title":"Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents","volume":"34","author":"Alhamar","year":"2021","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-020-05599-1","article-title":"Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2\/CEP17 ratio in HER2-overexpressing breast cancer: analysis of the National Cancer Database (NCDB)","volume":"181","author":"Greenwell","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib37","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.1634\/theoncologist.2018-0611","article-title":"Prognostic Value of HER2 to CEP17 ratio on fluorescence in situ hybridization ratio in patients with nonmetastatic HER2-positive inflammatory and noninflammatory breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab","volume":"25","author":"Ogawa","year":"2020","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.modpat.2026.101074_bib38","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1158\/1078-0432.CCR-16-2373","article-title":"Pathological complete response to neoadjuvant trastuzumab is dependent on HER2\/CEP17 ratio in HER2-amplified early breast cancer","volume":"23","author":"Singer","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.modpat.2026.101074_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023053","article-title":"Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer","volume":"99","author":"Choi","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib40","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/bjc.2014.147","article-title":"Impact of HER2 copy number in IHC2+\/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network","volume":"110","author":"Borley","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib41","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.3390\/ijms24043590","article-title":"HER2 amplification level predicts pathological complete response in the neoadjuvant setting of HER2-overexpressing breast cancer: a meta-analysis and systematic review","volume":"24","author":"Gonullu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"35","key":"10.1016\/j.modpat.2026.101074_bib42","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Gomez-Martin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib43","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41379-021-00813-x","article-title":"HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity","volume":"34","author":"Pol\u00f3nia","year":"2021","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12282-020-01208-7","article-title":"ER staining levels affect HER2 staining and heterogeneity","volume":"28","author":"Akashi","year":"2021","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1309\/AJCPXTZSKBRIP07W","article-title":"Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity","volume":"136","author":"Allison","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101074_bib46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-017-2189-9","article-title":"Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization","volume":"471","author":"Pol\u00f3nia","year":"2017","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib47","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10549-012-2046-0","article-title":"Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance","volume":"134","author":"Yang","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib49","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/jclinpath-2012-201403","article-title":"Clinicopathological significance of HER2\/neu genetic heterogeneity in HER2\/neu nonamplified invasive breast carcinomas and its concurrent axillary metastasis","volume":"66","author":"Shafi","year":"2013","journal-title":"J Clin Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib50","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1309\/AJCPATBZ2JFN1QQC","article-title":"HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations","volume":"137","author":"Starczynski","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib51","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/his.13733","article-title":"Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status, and potential treatment benefits","volume":"74","author":"Pekar","year":"2019","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.modpat.2026.101074_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","article-title":"'Genetic heterogeneity' in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00428-019-02567-z","article-title":"What to expect from the 2018 ASCO\/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?","volume":"475","author":"Curado","year":"2019","journal-title":"Virchows Arch"},{"issue":"7","key":"10.1016\/j.modpat.2026.101074_bib54","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101074_bib55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","article-title":"Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma","volume":"59","author":"Kim","year":"2011","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.modpat.2026.101074_bib56","doi-asserted-by":"crossref","first-page":"9262","DOI":"10.18632\/oncotarget.24265","article-title":"Prognostic implications of HER2 heterogeneity in gastric cancer","volume":"9","author":"Motoshima","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib57","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.humpath.2013.11.004","article-title":"Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization","volume":"45","author":"Tajiri","year":"2014","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.modpat.2026.101074_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153229","article-title":"Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer","volume":"216","author":"Zhang","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"9","key":"10.1016\/j.modpat.2026.101074_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153090","article-title":"HER2 genomic heterogeneity is a frequent event in gastroesophageal adenocarcinoma and correlates with tumor morphology","volume":"216","author":"Machado-Neves","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4132\/jptm.2017.04.24","article-title":"HER2 status and its heterogeneity in gastric carcinoma of Vietnamese patient","volume":"51","author":"Phan","year":"2017","journal-title":"J Pathol Transl Med"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10120-014-0394-7","article-title":"A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity","volume":"18","author":"Nishida","year":"2015","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib62","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/cas.12886","article-title":"Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: a comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization","volume":"107","author":"Kanayama","year":"2016","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.modpat.2026.101074_bib63","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Juza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2026.101074_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2025.104240","article-title":"Analysis of human epidermal growth factor receptor 2 (HER2) Heterogeneity at the protein and gene levels in endometrial cancer: refining HER2 reporting and HER2-directed therapies","volume":"105","author":"Menshikova","year":"2025","journal-title":"Lab Invest"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib65","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00535-022-01879-3","article-title":"Gastric cancer and genomics: review of literature","volume":"57","author":"Onoyama","year":"2022","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib67","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-022-00324-1","article-title":"Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling","volume":"6","author":"Kohsaka","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"25","key":"10.1016\/j.modpat.2026.101074_bib68","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2026.101074_bib69","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib70","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/cr.2012.78","article-title":"Receptor tyrosine kinases in cancer escape from BRAF inhibitors","volume":"22","author":"Lo","year":"2012","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib71","first-page":"1225","article-title":"Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic\/recurrent sites: HER2 gene amplification and p53 mutation","volume":"22","author":"Sekido","year":"2003","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pin.12290","article-title":"Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: clinicopathological study of three autopsy cases and one resected case","volume":"65","author":"Saito","year":"2015","journal-title":"Pathol Int"},{"issue":"5","key":"10.1016\/j.modpat.2026.101074_bib73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/modpathol.2012.205","article-title":"Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas","volume":"26","author":"Cho","year":"2013","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1676","article-title":"HER2 gene status in primary breast cancers and matched distant metastases","volume":"9","author":"Tapia","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"6","key":"10.1016\/j.modpat.2026.101074_bib75","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2010.33.8889","article-title":"Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors","volume":"30","author":"Niikura","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-020-05935-5","article-title":"Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer","volume":"185","author":"Van Raemdonck","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.modpat.2026.101074_bib77","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J Pathol Transl Med"},{"issue":"9","key":"10.1016\/j.modpat.2026.101074_bib79","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/PAI.0000000000000136","article-title":"HER2 genetic heterogeneity in gastric cancer: evaluation according to the College of American Pathologists Breast Cancer Criteria","volume":"23","author":"Treacy","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1309\/5J4008QRY1HWW5W4","article-title":"Sarcomatoid variant of salivary duct carcinoma: clinicopathologic and immunohistochemical study of eight cases with review of the literature","volume":"122","author":"Nagao","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101074_bib81","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/ajcp\/aqy136","article-title":"Identification of HER2 immunohistochemistry-negative, FISH-amplified breast cancers and their response to anti-HER2 neoadjuvant chemotherapy","volume":"151","author":"Gibbons-Fideler","year":"2019","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101074_bib82","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clbc.2021.05.004","article-title":"Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression\/gene amplification in breast cancer in the modern age: a single institution experience and pooled literature review study","volume":"22","author":"Memon","year":"2022","journal-title":"Clin Breast Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2026.101074_bib83","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jclinpath-2012-200885","article-title":"Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes","volume":"65","author":"Alvarenga","year":"2012","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101074_bib84","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2026.101074_bib85","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","article-title":"Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility","volume":"31","author":"Moktefi","year":"2018","journal-title":"Mod Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:41:27Z","timestamp":1792104087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":84,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001171"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101074","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101074"}}